Replies to post #296342 on Amarin Corp Plc (AMRN)

[momoney24]

I think what he meant was generics will intentionally hold out a few more years to allow us to build market for them... but I probably shouldn’t be speaking for someone who is infinitely smarter than I

[alm2]

Kiwi
Amarin can spend to build but can still make a profit as they do so ... I presume
So for example getting the market big and fat through Amarin’s efforts - and Amarin make money whilst on the way enables generics to enter at a profitable point for them

The generics will know how much they need to sell to turn a profit - if market and share of market not big enough - no profit
Alm

[dukesking]

Kiwi, have you read the exchanges between Hamoa and myself? It will provide context to his statement. He was stating that any agreement to encourage delay of entry by generics is considered pay to delay and it’s illegal. Therefor any agreement between AMRN and generics would have to be an undocumented partnership/business agreement/joint venture or whatever you want to call it, with the end game being generics agreeing to wait until 2026-27 before entering, in return for a financial considerations. This avoids asking courts to vacate ruling on settlement terms. Hope I got that right Hamoa.

[Hamoa]

Happy to explain may take on this.

I used the term "joint venture" to capture the fact that both Amarin and the generics want the same thing. They all want to see the largest possible US market for Vascepa. The only way that happens is if Amarin continues a full-court marketing push based on the CV indication. If Amarin pulls back those efforts, everyone loses in the long run. If Amarin continues those efforts, with the informal understanding that generics remain out of the market until it's more mature, then everyone wins in the end. It's not the long-term exclusivity that Amarin had hoped for, but it gives them several lucrative years of de facto US exclusivity while they build their ROW business. The generics enter when the market is firmly established, at which point they each capture maybe $1B+ in annual revenues for what could be many years. The alternative is they enter now and they generate maybe $100M in annual revenues, with no legal ability to grow the market through promotion of the primary growth driver (CV indication), which Amarin controls exclusively.